Status:
RECRUITING
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Lead Sponsor:
Dallas VA Medical Center
Conditions:
Esophagus Adenocarcinoma
Esophagus Squamous Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Esophageal cancer, which has a low 5-year overall survival rate for all stages (\<20%) , is increasing in incidence. Previous studies have shown that the Hedgehog (Hh) and AKT signaling pathways are a...
Detailed Description
Esophageal cancer has a high incidence rate in the United States, and novel approaches to its treatment are being studied. Itraconazole, an antifungal agent, has been shown to inhibit the Hedgehog (Hh...
Eligibility Criteria
Inclusion
- Patients diagnosed with localized (locoregional) esophageal cancer
- Patients diagnosed with localized (locoregional) gastroesophageal junction cancer
Exclusion
- Patients unwilling or unable to provide informed consent
- Patients with QTc\>450ms
- Patients with a history of symptomatic congestive heart failure
- Patients with LFT's\>3xULN
- Patients who are pregnant
- Patients with a known allergy to itraconazole
Key Trial Info
Start Date :
June 24 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 29 2026
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT04018872
Start Date
June 24 2019
End Date
September 29 2026
Last Update
November 4 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dallas VA Medical Center
Dallas, Texas, United States, 75216